Stock listing

Replimune Group, Inc.

Selected listing: 7R8 · MUN · EUR · DE

Replimune Group, Inc. (Munich:7R8), Health Technology. Latest release Oct 1, 2026: Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

7R8:MUNEURDEUpdated September 25, 2026

Ticker: Munich:7R8
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Munich
Currency: EUR

Latest news from Replimune Group, Inc.

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

October 1, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

September 30, 2026

Replimune to Present at the Cantor Global Healthcare Conference 2026

September 3, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026

Replimune Announces Pricing of $150 Million Underwritten Offering

August 10, 2026

All Replimune Group, Inc. news →

Events

Replays

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call
Thu, May 22, 2025 · 08:00 AM ET
Watch

Research Replimune Group, Inc.

Replimune Group, Inc. company profile

View the public company page for Replimune Group, Inc. on 6ix.

Replimune Group, Inc. news

Read company news and market updates connected to Replimune Group, Inc..

Replimune Group, Inc. investor events

Find investor webinars, events, and replay context for Replimune Group, Inc..